LLY and the GLP-1 Franchise: What the Options Market Knows That the Headlines Don’t
Eli Lilly's Q1 blowout reset the ceiling — and the options flow is telling a very specific story
Eli Lilly's Q1 blowout reset the ceiling — and the options flow is telling a very specific story
A landmark CHIPS Act deal and a commercial hardware breakthrough are changing the conversation around this volatile pure-play.
Mounjaro up 125%. Zepbound up 79%. A new oral pill just launched. The growth story keeps widening.
Occidental Petroleum is at the center of a commodity supercycle that Wall Street is still underestimating
49% revenue growth, a doubling credit card portfolio, and a stock down nearly 40% from its highs. Something doesn't add…